Last updated: 2026-09-09 04:54:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Keros Therapeutics, Inc. (KROS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $11,19, with a market capitalization of $224,44M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9,69 to $22,55. This page covers its latest market performance, valuation, price trends and company information.
$224,44M | |
$11,16 | |
$88,80 | |
$9,12 | |
$11,32 | |
56,94K | |
239,53K | |
-- | |
$22,55 | |
$9,69 | |
-- | |
-- |
Keros Therapeutics, Inc. (KROS) last closed at $11,32 as of 2026-09-08 23:56:00, unchanged from the previous close of $11,32.
During the latest regular trading session, KROS traded between $9,12 and $88,80, with a volume of 56,94K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Keros Therapeutics, Inc. (KROS) moved from $11,23 to $11,19, representing a decline of 0,39% ($0,04).
The stock traded between $10,58 and $11,49 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 149,20 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 11,6%
KROS is currently trading at $11,19, placing it 11,6% of the way from its 52-week low of $9,69 to its 52-week high of $22,55. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 92 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Keros Therapeutics, Inc. (KROS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.